or Try an Advanced Search...

    Technical Analysis for UNCY - Unicycive Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 0.50 -6.52% -0.03
    UNCY closed down 6.52 percent on Friday, November 1, 2024, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical UNCY trend table...
    Date Alert Name Type % Chg
    Bearish Engulfing Bearish 0.00%
    Stochastic Sell Signal Bearish 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Spinning Top Other -6.52%
    Calm After Storm Range Contraction -6.52%
    Upper Bollinger Band Walk Strength -6.52%
    Wide Bands Range Expansion -6.52%
    Older End-of-Day Signals for UNCY ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 19 hours ago
    Down 5% about 21 hours ago
    Down 3% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 2 % about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    UNCY Chart by TradingView
    Basic chart:

    Profile

    Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Kidney Disease Kidney Nephrology Organ Failure Acute Kidney Injury Hyperphosphatemia Chemical Entity

    Is UNCY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 16 Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
    Oct 16 Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
    Oct 9 Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
    Sep 20 Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
    Sep 16 Life Sciences Virtual Investor Forum Agenda Announced for September 19th
    Sep 16 Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
    Sep 5 Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 21 Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
    Aug 14 Unicycive Therapeutics GAAP EPS of -$0.29
    Aug 14 Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
    See more UNCY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.818
    52 Week Low 0.202
    Average Volume 1,514,869
    200-Day Moving Average 0.80
    50-Day Moving Average 0.40
    20-Day Moving Average 0.43
    10-Day Moving Average 0.46
    Average True Range 0.05
    RSI (14) 62.26
    ADX 23.97
    +DI 26.36
    -DI 14.05
    Chandelier Exit (Long, 3 ATRs) 0.41
    Chandelier Exit (Short, 3 ATRs) 0.48
    Upper Bollinger Bands 0.53
    Lower Bollinger Band 0.32
    Percent B (%b) 0.85
    BandWidth 50.18
    MACD Line 0.03
    MACD Signal Line 0.02
    MACD Histogram 0.0111
    Fundamentals Value
    Market Cap 17.38 Million
    Num Shares 34.8 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -0.34
    Price-to-Sales 57.15
    Price-to-Book 11.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.61
    Resistance 3 (R3) 0.61 0.58 0.59
    Resistance 2 (R2) 0.58 0.55 0.58 0.58
    Resistance 1 (R1) 0.54 0.54 0.52 0.54 0.58
    Pivot Point 0.51 0.51 0.50 0.51 0.51
    Support 1 (S1) 0.47 0.48 0.45 0.46 0.42
    Support 2 (S2) 0.44 0.46 0.43 0.42
    Support 3 (S3) 0.40 0.44 0.41
    Support 4 (S4) 0.39